PBAC's latest decision on Abiraterone acetate and prednisolone: Recommended with restriction (2025). Considered for Treatment of patients with metastatic castration resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) or patients with mCRPC who have received prior chemotherapy containing a taxane.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Patients with metastatic castration resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) or patients with mCRPC who have received prior chemotherapy containing a taxane, with WHO performance status of 2 or less, not in combination with chemotherapy, and not having experienced disease progression on prior novel hormonal drugs.
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
abiraterone acetate 500 mg tablets (Zytiga) and prednisolone 5 mg tablets (Panafcortelone) used concomitantly
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.